Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm

Cancer Family

Malignant Neoplasm

CI-CAN-00000025CAExplore in graph →

20,116 active trials259 approved drugs3,741 evidence items

NCIt: C9305
OncoTree: MT
DOID: 162
UMLS CUI: C0006826

Overview
Statistics
Survival
Genomics442
Variants & evidence3741
Drugs424
Trials90685
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,349)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,026–4,050 of 4,349 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
· PLoS One · 2011 · PMID 22194965 · validated civic_curation pubmed
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
· Gynecol Oncol · 2005 · PMID 15790433 · validated civic_curation pubmed
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
· Oncotarget · 2015 · PMID 26304929 · validated civic_curation pubmed
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
· Proc Natl Acad Sci U S A · 2013 · PMID 24277854 · validated civic_curation pubmed
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
· Breast Cancer Res · 2009 · PMID 19874578 · validated civic_curation pubmed
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.
· J Pathol Clin Res · 2016 · PMID 27499916 · validated civic_curation pubmed
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.
· Proc Natl Acad Sci U S A · 2012 · PMID 22203985

Showing 4,026–4,050 of 4,349 publications

← Previous
1
…
161
162
163
…
174
Next →

· validated civic_curation

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.

· Oncotarget · 2015 · PMID 26204491 · validated civic_curation pubmed

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

· Oncotarget · 2017 · PMID 28947956 · validated civic_curation pubmed

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

· PLoS One · 2016 · PMID 27391784 · validated civic_curation pubmed

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

· Oncotarget · 2016 · PMID 26689995 · validated civic_curation pubmed

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.

· Br J Cancer · 2007 · PMID 17224927 · validated civic_curation pubmed

Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

· Oncotarget · 2016 · PMID 27286459 · validated civic_curation pubmed

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

· PLoS One · 2011 · PMID 22046346 · validated civic_curation pubmed

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

· Blood · 2000 · PMID 11050000 · validated civic_curation pubmed

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

· Blood · 2006 · PMID 16497971 · validated civic_curation pubmed

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

· Int J Mol Med · 2009 · PMID 19513541 · validated civic_curation pubmed

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

· Int J Cancer · 2012 · PMID 21732342 · validated civic_curation pubmed

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.

· Int J Cancer · 2009 · PMID 19035443 · validated civic_curation pubmed

Characteristics of lung cancers harboring NRAS mutations.

· Clin Cancer Res · 2013 · PMID 23515407 · validated civic_curation pubmed

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

· Cancer Res · 2008 · PMID 18632602 · validated civic_curation pubmed

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

· Proc Natl Acad Sci U S A · 2005 · PMID 16046538 · validated civic_curation pubmed

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

· Future Oncol · 2015 · PMID 26161928 · validated civic_curation pubmed

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.

· Oncogene · 2011 · PMID 21132006 · validated civic_curation pubmed

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

· Leukemia · 2016 · PMID 26582647 · validated civic_curation pubmed